Literature DB >> 26149659

Impact of the source of hematopoietic stem cell in unrelated transplants: comparison between 10/10, 9/10-HLA matched donors and cord blood.

Clémence Granier1, Lucie Biard2, Emeline Masson1, Raphaël Porcher2, Régis Peffault de Latour3, Marie Robin3, Nicolas Boissel4, Alienor Xhaard3, Patricia Ribaud3, Etienne Lengline4, Jérôme Larghero5, Dominique Charron1, Pascale Loiseau1, Gérard Socié3,6,7, Nathalie Dhédin4.   

Abstract

In absence of available matched-related or unrelated donor (MUD), mismatched unrelated donors (MMUD) and unrelated cord blood (UCB) are both considered to be suitable donors, with similar post-transplant overall survival. In most of these retrospective comparisons, HLA typing of adult donors was performed at eight loci. The aim of this study was to compare the outcome of patients transplanted from UCB (N = 64) with those transplanted from 9/10-HLA MMUD (N = 84) or 10/10-HLA MUD (N = 196). In multivariate analysis, UCB was associated with less Grade II-IV acute GVHD in comparison with MUD (aHR 1.97, 95% CI 1.19-3.27, P = 0.009) and MMUD transplants (aHR 1.79, 95% CI 1.02-3.15, P = 0.042), while the cumulative incidence of chronic GVHD was not significantly different between the three groups. Overall survival (OS), non-relapse mortality, and relapse were not different between MMUD and UCB transplantation, whereas OS was impaired after UCB in comparison with MUD (aHR 0.65, 95% CI 0.43-0.99, P = 0.043). Factors also impacting OS were the donor/recipient CMV serostatus (Donor-/Recipient+ aHR 1.76, 95% CI 1.23-2.52, P = 0.002 compared with D-/R-), the donor/recipient gender combination (Female/Male versus other combinations aHR 1.57, 95% CI 1.11-2.22, P = 0.012) and disease risk (aHR 1.58, 95% CI 1.05-2.38, P = 0.027 for high vs. low risk disease). Our data confirm that UCB and 9/10-HLA MMUD are both relevant alternative options when no 10/10-HLA donor is available. Donor/recipient gender combination and CMV serostatus had a significant impact on survival and may be taken into account, along with donor type, in the setting of MMUD and UCB transplants.
© 2015 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2015        PMID: 26149659     DOI: 10.1002/ajh.24112

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  5 in total

1.  Dynamical System Modeling to Simulate Donor T Cell Response to Whole Exome Sequencing-Derived Recipient Peptides Demonstrates Different Alloreactivity Potential in HLA-Matched and -Mismatched Donor-Recipient Pairs.

Authors:  Badar Abdul Razzaq; Allison Scalora; Vishal N Koparde; Jeremy Meier; Musa Mahmood; Salman Salman; Max Jameson-Lee; Myrna G Serrano; Nihar Sheth; Mark Voelkner; David J Kobulnicky; Catherine H Roberts; Andrea Ferreira-Gonzalez; Masoud H Manjili; Gregory A Buck; Michael C Neale; Amir A Toor
Journal:  Biol Blood Marrow Transplant       Date:  2015-12-11       Impact factor: 5.742

2.  Risk Factors for Graft-Versus-Host Disease After Transplantation of Hematopoietic Stem Cells from Unrelated Donors in the China Marrow Donor Program.

Authors:  Fan Yang; Daopei Lu; Yu Hu; Xiaojun Huang; He Huang; Jing Chen; Depei Wu; Jianmin Wang; Chun Wang; Mingzhe Han; Hu Chen
Journal:  Ann Transplant       Date:  2017-06-27       Impact factor: 1.530

3.  Disability related to chronic graft -versus-host disease after alternative donor hematopoietic cell transplantation.

Authors:  Giancarlo Fatobene; Barry E Storer; Rachel B Salit; Stephanie J Lee; Paul J Martin; Guang-Shing Cheng; Paul A Carpenter; Gansuvd Balgansuren; Effie W Petersdorf; Colleen Delaney; Brenda M Sandmaier; Filippo Milano; Mary E Flowers
Journal:  Haematologica       Date:  2018-11-15       Impact factor: 9.941

4.  Sequence Variations Within HLA-G and HLA-F Genomic Segments at the Human Leukocyte Antigen Telomeric End Associated With Acute Graft-Versus-Host Disease in Unrelated Bone Marrow Transplantation.

Authors:  Shingo Suzuki; Satoko Morishima; Makoto Murata; Masafumi Tanaka; Atsuko Shigenari; Sayaka Ito; Uma Kanga; Jerzy K Kulski; Yasuo Morishima; Takashi Shiina
Journal:  Front Immunol       Date:  2022-07-21       Impact factor: 8.786

5.  Pitfalls of haplotype phasing from amplicon-based long-read sequencing.

Authors:  Thomas W Laver; Richard C Caswell; Karen A Moore; Jeremie Poschmann; Matthew B Johnson; Martina M Owens; Sian Ellard; Konrad H Paszkiewicz; Michael N Weedon
Journal:  Sci Rep       Date:  2016-02-17       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.